Revenue ₹8,646 Cr
0 met · 0 close · 18 missed across 18 tracked promises
View all executive profiles for Aurobindo Pharma LimitedAurobindo Pharma reported a strong quarter with PAT of INR 910 crore, supported by improving Pen G yields and a favor...
0% promises delivered
Based on 18 tracked promises across 11 quarters
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Quarterly Earnings Timeline
Financial verification status, call summary, sentiment, and management-delivery signals by quarter.
Q3 FY26
12 Feb 2026
Revenue ₹8,646 Cr
Aurobindo Pharma reported a strong quarter with PAT of INR 910 crore, supported by improving Pen G yields and a favorable government MIP policy on key antibiotics.
bullish
high
2 missed
Read full analysis →
Q2 FY26
14 Nov 2025
Revenue ₹8,286 Cr (+6% YoY)
Aurobindo Pharma reported Q2 FY26 consolidated revenue of INR 8,286 crore (+6% YoY) and EBITDA of INR 1,678 crore (20.3% margin, +7% YoY).
bullish
high
2 missed
Read full analysis →
Q1 FY26
14 Aug 2025
Revenue ₹7,868 Cr (+4% YoY)
Aurobindo Pharma reported a steady Q1 FY26 with consolidated revenue of INR 7,878 crore (+4% YoY) and EBITDA of INR 1,603 crore (+12% YoY), despite a significant reduc...
neutral
medium
1 missed
Read full analysis →
Q4 FY25
15 May 2025
Revenue ₹8,382 Cr (+11% YoY)
Aurobindo Pharma delivered a strong Q4 FY25 with revenue of INR 8,382 crore (+11% YoY) and EBITDA of INR 1,792 crore (21.4% margin), driven by volume growth in US and...
bullish
high
1 missed
Read full analysis →
Q3 FY25
12 Feb 2025
Revenue ₹7,979 Cr
Aurobindo Pharma delivered its highest-ever quarterly revenue of INR 7,979 crore in Q3 FY25, driven by robust US base product sales, strong European growth (+23% YoY),...
bullish
high
1 missed
Read full analysis →
Q2 FY25
11 Nov 2024
Revenue ₹7,796 Cr (+8% YoY)
Aurobindo Pharma delivered a steady Q2 FY25 with revenue of INR 7,796 crore (+8% YoY) and EBITDA margin of 20.1%, despite higher R&D costs and penicillin G ramp-up los...
bullish
high
3 missed
Read full analysis →
Q1 FY25
12 Aug 2024
Revenue ₹7,567 Cr (+10% YoY)
Aurobindo Pharma reported a solid Q1 FY25 with revenue of INR 7,567 crore (+10% YoY) and PAT of INR 919 crore (+61% YoY), driven by strong performance in Europe (EUR 2...
bullish
medium
2 missed
Read full analysis →
Q4 FY24
27 May 2024
Revenue ₹7,580 Cr (+17% YoY)
Aurobindo Pharma delivered a strong Q4 FY24 with revenue of INR 7,850 crore (+17% YoY) and EBITDA of INR 1,687 crore (+68% YoY), driven by volume gains, new product la...
bullish
high
2 missed
Read full analysis →
Q3 FY24
12 Feb 2024
Revenue ₹7,352 Cr (+14.7% YoY)
Aurobindo Pharma reported Q3 FY24 revenue of INR 7,352 crore (+14.7% YoY) and EBITDA margin of 21.8%, driven by strong US formulation growth (+28.9% YoY) and injectabl...
bullish
medium
3 missed
Read full analysis →
Q2 FY24
09 Nov 2023
Revenue ₹7,219 Cr (+25.8% YoY)
Aurobindo Pharma delivered a strong Q2 FY24 with revenue of INR 7,219 crore (+25.8% YoY), EBITDA of INR 1,403 crore (+67.7% YoY), and PAT of INR 752 crore (+83.6% YoY).
bullish
high
1 missed
Read full analysis →
Q1 FY24
14 Aug 2023
Revenue ₹6,850 Cr (+9.9% YoY)
Aurobindo Pharma delivered a robust Q1 FY24 with revenue of INR 6,850 crore (+9.9% YoY) and EBITDA of INR 1,151 crore (+19.3% YoY), driven by strong US formulation gro...
bullish
high
Scorecard starts after historical backfill
Read full analysis →